Hematologic Malignancies Market Size, Share & Trends Analysis Report by Type (Leukemia, Lymphoma, Multiple Myeloma), By Therapy (Chemotherapy, Radiotherapy, Immunotherapy), And Segment Forecasts, 2018 - 2025

Industry Insights

The global hematologic malignancies market size was valued at USD 35.6 billion in the year 2016 with a CAGR of 10.48%. Growing incidence of blood cancer and increasing focus on the development of new treatments are expected to drive the market. Globally, blood malignancies are the fifth most common cancer and is the second most leading cause of cancer deaths. The three most common types of blood cancers are leukemia, lymphoma, and multiple myeloma. Worldwide, more than 300,000 people are diagnosed with leukemia and 400,000 people are diagnosed with lymphoma each year 

The highest number of acquisitions and collaborations are happening in the oncology segment where big pharma players are collaborating with each other. In 2015, cancer therapeutics witnessed a significant number of collaborations, which reflects the interest in this segment. Various organizations and research institutes around the world are collaborating to develop novel therapies for hematologic malignancies.

Furthermore, formulations of new regulatory approvals for new drugs for blood cancer are expected to boost the growth of hematologic malignancies market. For instance, in 2015, Pfizer announced that inotuzumab (antibody-drug conjugate) received a breakthrough therapy designation from U.S. FDA for acute lymphoblastic leukemia.

Increasing awareness amongst healthcare professionals and patients about the possibility of early diagnosis of cancer and increase in government funding for research is anticipated to accelerate the market growth during the forecast period. Institutes like National Cancer Institute (NCI) receive funds from U.S. congress to support cancer-related activities. 

Type Insights

Based on type, the market is categorized into leukemia, lymphoma, and multiple myeloma. Leukemia is further categorized into acute lymphocytic, chronic lymphocytic, acute myeloid, and chronic myeloid leukemia. Acute lymphocytic leukemia is the most prevalent type of leukemia, which accounted for 56% of cases in adolescents and 80% in children from 2016 to 2017. 

Leukemia was the largest segment in 2016, owing to the presence of best-selling brands like Rituxan, Imbruvica, and Glivec, which are reported to be some of the highest revenue-generating oncology drugs. Acute myeloid is expected to witness the fastest growth over the forecast period due to the presence of a strong product pipeline and its expected commercialization.

Therapy Insights

The therapy segment is further categorized into chemotherapy, radiotherapy, immunotherapy, and stem cell transplantation. Chemotherapy was the largest segment in 2016, as it is the first line of treatment. For most types of blood cancer, chemotherapy is the usual treatment and a particular drug or combination of drugs are used, based on the type of cancer. 

Immunotherapy is estimated to witness the fastest growth of 11.2% over the forecast. Effectiveness of the treatment, lower adverse effects, and presence of brands like Rituxan, Revlimid, Mabthera, Gazyva, and Arzerra are responsible for the growth of this segment.

Regional Insights

North America dominated the hematologic malignancy market, and it held the market share of over 39% in 2016. Presence of key players, established healthcare infrastructure, and availability of branded drugs are some of the factors responsible for its large share. Besides, favorable government initiatives and increase in number of research collaborations are some of the drivers expected to accelerate the market growth. 

Asia Pacific is estimated to be the fastest-growing over the forecast period with CAGR of around 12.5%, owing to the increase in healthcare expenditure, rising awareness about early diagnosis, high unmet clinical needs of patients, and availability of effective treatment in emerging countries, such as China and India.

Hematologic Malignancies Market Share Insights

Some of the key players in this industry are Pfizer, Inc.; F. Hoffmann-LA Roche ltd; Sanofi-Aventis; Bristol-Myers Squibb Company; AbbVie, Inc.; Novartis AG; GlaxoSmithKline PLC; Celgene Corporation; Johnson & Johnson Services, Inc.; and Takeda Pharmaceutical Company Limited.

Key players are focusing on expanding their businesses in developing regions to increase their market share. In addition, they are adopting strategies such as mergers & acquisitions and new product development. For instance, AbbVie acquired Pharmacyclics, Inc., a leader in the hematologic oncology market. With this acquisition, they aim to expand their presence in scientific and commercial oncology.

Report Scope

Segments Covered in the report

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For this study, Grand View Research has segmented the global hematologic malignancies market based on type, therapy, and region:

• Type Outlook (Revenue, USD Billion, 2014 - 2025)

  • Leukemia

    • Acute Lymphocytic Leukemia

    • Chronic Lymphocytic Leukemia

    • Acute Myeloid Leukemia

    • Chronic Myeloid Leukemia

  • Lymphoma

  • Multiple Myeloma

  • Others

• Therapy Outlook (Revenue, USD Billion, 2014 - 2025)

  • Chemotherapy

  • Radiotherapy

  • Immunotherapy

  • Stem Cell Transplantation

  • Others

• Regional Outlook (Revenue, USD Billion, 2014 - 2025)

  • North America

    • The U.S.

    • Canada

  • Europe

    • Germany

    • The U.K.

  • Asia Pacific

    • China

    • Japan

  • Latin America

    • Brazil

  • Middle East & Africa

    • South Africa